Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.

Kriya Therapeutics, a US-based developer of gene therapies based on research at Stanford University, has closed a $100m series B round led by investment firm Patient Square Capital. The transaction featured pharmaceutical firm Dexcel Pharma, QVT Financial, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund. Woodline Partners LP, CAM Capital,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.